Subject category:
Strategy and General Management
Published by:
Harvard Business Publishing
Version: 14 August 2015
Revision date: 11-Sep-2015
Length: 27 pages
Data source: Field research
Topics:
Consolidation; Fair treatment; Health care; Public health; Regional economic integration; Shanghai Stock Exchange; Vertical integration; Globalization strategies; Decision making; Mergers & acquisitions (M&A); Subsidiaries; Incubators; General management; Execution; Conglomerates; State-owned enterprises
Share a link:
https://casecent.re/p/117929
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
Shanghai Pharmaceuticals (SPH), a vertically integrated Chinese pharmaceutical conglomerate, was considering its strategic options in the context of a rapidly evolving industry, policy, and economic environment. The company - essentially a collection of subsidiaries operating under a unified management structure - was formed through the 2009 merger of several state-owned enterprises, part of a broad policy effort in China to streamline state assets, consolidate the fragmented pharmaceutical sector, and enhance the global competitiveness of domestic firms. As it competed with other large domestic firms to become one of the few national champions that the government hoped to create, SPH was also considering an acquisition in the US or Europe. This case allows students to consider the broad trends sweeping China's pharmaceutical industry and health care sector and assess future opportunities there for domestic and foreign businesses.
Location:
About
Abstract
Shanghai Pharmaceuticals (SPH), a vertically integrated Chinese pharmaceutical conglomerate, was considering its strategic options in the context of a rapidly evolving industry, policy, and economic environment. The company - essentially a collection of subsidiaries operating under a unified management structure - was formed through the 2009 merger of several state-owned enterprises, part of a broad policy effort in China to streamline state assets, consolidate the fragmented pharmaceutical sector, and enhance the global competitiveness of domestic firms. As it competed with other large domestic firms to become one of the few national champions that the government hoped to create, SPH was also considering an acquisition in the US or Europe. This case allows students to consider the broad trends sweeping China's pharmaceutical industry and health care sector and assess future opportunities there for domestic and foreign businesses.
Settings
Location: